A deal to buy Hampshire-based drugs firm Shire is a step closer after its board backed a new takeover proposal worth more than £31 billion.
Shire's support for the higher offer from US-based AbbVie is dependent on a number of conditions being met.
Founded in the UK in 1986, Shire is best known for its attention deficit disorder drugs. It is listed on the London Stock Exchange, has its tax base in Dublin and sells most of its products in North America.
AbbVie's pursuit of Shire comes just weeks after UK firm AstraZeneca fought off takeover interest worth £69 billion from US drugs giant Pfizer.
AbbVie, which has until Friday to confirm an offer for Shire, plans to move its domicile to the UK in a move that would cut its corporate tax rate.
The Illinois-based company was formed in January 2013 after it was spun off from Abbott Laboratories. It employs around 25,000 people worldwide and markets medicines in more than 170 countries.
Shire held talks with AbbVie over the weekend following the receipt of proposals in which its shareholders would hold 25% of the combined business. The proposal values Shire at £53.20 a share, equivalent to £31.35 billion.
AbbVie first approached Shire at the start of May, with the third proposal by the end of that month valuing the company at 4626p a share, or £27.2 billion.
Shire's products enable people with life-altering conditions to lead better lives.
It provides treatments in areas such as rare diseases and neuroscience and is developing products in other therapeutic areas. Basingstoke-based Shire's best selling product is hyperactivity drug Vyvanse, which achieved revenues of 1.2 billion US dollars (£703 million) last year.
The pharmaceuticals sector has seen a raft of deal-making in recent months, with US companies looking to Europe as a way to reduce their tax liabilities.
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules hereComments are closed on this article